Theoretical Study on the Metabolic Mechanism of Heptachlor in Human Cytochrome P450 Enzymes

被引:0
|
作者
Zhao, Xuerui [1 ]
Zhang, Hao [1 ]
Shen, Xiaoli [1 ]
Zheng, Qingchuan [2 ]
Wang, Song [1 ]
机构
[1] Jilin Univ, Inst Theoret Chem, Changchun 130021, Peoples R China
[2] Jilin Univ, Sch Pharmaceut Sci, Changchun 130021, Peoples R China
关键词
heptachlor; cytochrome P450 enzyme; metabolic mechanism; MD simulation; QM calculation; MOLECULAR-DYNAMICS; SIDE PRODUCTS; COMPOUND-I; P450; 2A6; 3A4; SELECTIVITY; REACTIVITY; OXIDATION; EPOXIDE;
D O I
10.3390/ijms26052021
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Heptachlor (HEP) is an insecticide metabolized by cytochrome P450 (CYP) enzymes in the human liver, resulting in the formation of heptachlor epoxide (HEPX). HEPX can persist in the human body for a long duration. Therefore, it can be extremely harmful. A comprehensive understanding of HEP's metabolic fate may provide a theoretical basis for mitigating associated hazards. However, the specific human CYP isoforms that metabolize HEP, and their metabolic mechanisms, remain unclear. In this study, eight human CYP isoforms were used as catalytic enzymes to investigate the metabolic mechanism of HEP using molecular docking, molecular dynamics simulations, and quantum mechanical calculations. These results indicate that HEP primarily binds to CYP enzymes through hydrophobic interactions, and that the binding positions of HEP are determined by the composition and shape of the hydrophobic pockets near the active site. Based on the reaction distance, CYP2A6, CYP3A4, and CYP3A5 were the only three enzymes that could metabolize HEP. The epoxidation of HEP catalyzed by the doublet state of compound I was effectively concerted, and the rate-determining step was the electrophilic attack of the oxygen atom on HEP. The energy barriers of the rate-determining step vary significantly among different enzymes. A comparison of these energy barriers suggested that CYP3A5 is the most likely enzyme for HEP catalysis in humans.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Theoretical perspective on the structure and mechanism of cytochrome P450 enzymes
    Shaik, S
    Kumar, D
    de Visser, SP
    Altun, A
    Thiel, W
    CHEMICAL REVIEWS, 2005, 105 (06) : 2279 - 2328
  • [2] Theoretical study on the metabolic mechanisms of levmepromazine by cytochrome P450
    Yongting Wang
    Qiu Chen
    Zhiyu Xue
    Yan Zhang
    Zeqin Chen
    Ying Xue
    Journal of Molecular Modeling, 2016, 22
  • [3] Theoretical study on the metabolic mechanisms of levmepromazine by cytochrome P450
    Wang, Yongting
    Chen, Qiu
    Xue, Zhiyu
    Zhang, Yan
    Chen, Zeqin
    Xue, Ying
    JOURNAL OF MOLECULAR MODELING, 2016, 22 (10)
  • [4] Expression, Function and Regulation of Mouse Cytochrome P450 Enzymes: Comparison With Human Cytochrome P450 Enzymes
    Hrycay, E. G.
    Bandiera, S. M.
    CURRENT DRUG METABOLISM, 2009, 10 (10) : 1151 - 1183
  • [5] Impact of Mutant P450 Oxidoreductase on Metabolic Capacity of Cytochrome P450 Enzymes
    Tomalik-Scharte, Dorota
    Maiter, Dominique
    Kirchheiner, Julia
    Ivison, Hannah
    Fuhr, Uwe
    Arlt, Wiebke
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 104 (06) : 502 - 503
  • [6] Metabolic activation of chrysene by human hepatic and pulmonary cytochrome P450 enzymes
    Koehl, W
    Amin, S
    Yamazaki, H
    Ueng, YF
    Tateishi, T
    Guengerich, FP
    Hecht, SS
    POLYCYCLIC AROMATIC COMPOUNDS, 1996, 10 (1-4) : 59 - 66
  • [7] Cytochrome p450 enzymes
    Donaldson, D
    JOURNAL OF THE ROYAL SOCIETY FOR THE PROMOTION OF HEALTH, 2000, 120 (03): : 150 - 151
  • [8] Metabolism of Evodiamine by Human Cytochrome P450 Enzymes
    Fang, Zhong-Ze
    Yang, Ling
    DRUG METABOLISM REVIEWS, 2009, 41 : 99 - 99
  • [9] Oxidation of indole by human cytochrome P450 enzymes
    Guengerich, FP
    Cai, H
    Notley, LM
    DeVoss, JJ
    Gillam, EMJ
    FASEB JOURNAL, 2000, 14 (08): : A1436 - A1436
  • [10] Ipriflavone as an inhibitor of human cytochrome P450 enzymes
    Monostory, K
    Vereczkey, L
    Lévai, F
    Szatmári, I
    BRITISH JOURNAL OF PHARMACOLOGY, 1998, 123 (04) : 605 - 610